AriBio Co., Ltd.

The BioFuture conference in New York featured panels that got into the nitty-gritty of drug development – from using artificial intelligence to improve the efficiency of drug development, to finding i

Drug approvals in South Korea fell in calendar 2023 amid the shift of COVID-19 to endemic from pandemic status, as domestic pharma firms began to shift their focus back to normalized R&D activities af

AriBio Co., Ltd. is set to become the first South Korean pharma firm to begin a global Phase III clinical development program for a novel drug for Alzheimer’s disease (AD), following an IND approval

As South Korea seeks to foster the biohealth industry through various strategies including creating new markets, the Korea Health Industry Development Institute (KHIDI) is also making broad efforts in